PT-141 Research
Melanocortin Receptor Research Peptide
Research area: melanocortin pathways
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist studied for its activity at MC3 and MC4 receptors in the central nervous system. A pharmaceutical version (Vyleesi) received FDA approval for hypoactive sexual desire disorder (HSDD) in premenopausal women in 2019.
Research Areas
Melanocortin Receptor Signaling
Research focuses on PT-141's activity at MC3 and MC4 receptors and its downstream effects on dopamine and norepinephrine signaling pathways in the central nervous system.
Sexual Function Pathway Research
Studies examine its role in libido-related neural pathways, sexual arousal signaling, and desire-related CNS activity in both men and women. Phase 3 trials leading to Vyleesi's FDA approval enrolled over 1,200 women.
Mood & Motivation Signaling
Researchers investigate its influence on dopaminergic pathways involved in mood, motivation, and reward-system signaling research.
Energy & CNS Activation Research
Studies explore its role in central nervous system activation signaling, alertness pathways, and energy-related neurological research.
Vyleesi (bremelanotide) is FDA-approved for HSDD in premenopausal women. PT-141 as a research peptide is investigational for other uses. Not medical advice.
Research References
Discuss any health concerns with a licensed clinician before making health decisions.
Have questions about PT-141?
Request a free consultation to ask questions and learn more about this research area.
Affiliate disclosure: I am an independent affiliate of The Longevity Consultants and may receive compensation if you request a consultation through me.
Request a free consultation